Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
暂无分享,去创建一个
Nicolas Servant | Anne Vincent-Salomon | Xavier Paoletti | Vincent Servois | David Gentien | Virginie Bernard | Olivier Trédan | Maud Kamal | Sandrine Boyault | Pascal Jezequel | Mario Campone | S. Boyault | A. Vincent-Salomon | V. Servois | I. Bièche | X. Paoletti | M. Campone | N. Servant | V. Bernard | O. Trédan | M. Sablin | M. Kamal | D. Gentien | A. Gonçalves | N. Isambert | C. Le Tourneau | J. Delord | Ivan Bièche | Christophe Le Tourneau | C. Gavoille | C. Dubot | M. Massiani | C. Mauborgne | S. Armanet | P. Jézéquel | V. Attignon | Jean-Pierre Delord | Nicolas Isambert | Anthony Gonçalves | Marie-Paule Sablin | Céline Gavoille | Coraline Dubot | Marie-Ange Massiani | Cécile Mauborgne | Sebastien Armanet | Valéry Attignon | C. le Tourneau | Sébastien Armanet
[1] M. Krzyzanowska,et al. Off-label use of cancer drugs: a benchmark is established. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Gemma,et al. F1000 highlights , 2010 .
[3] Marc Buyse,et al. Adjuvant trastuzumab in HER2-positive breast cancer. , 2011, The New England journal of medicine.
[4] P. Ascierto,et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.
[5] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[6] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[7] J. Soria,et al. From theoretical synergy to clinical supra-additive toxicity. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Seiichiro Yamamoto,et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. , 2005, The New England journal of medicine.
[9] Francesca Molinari,et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. , 2010, The Journal of clinical investigation.
[10] Jane C Weeks,et al. Physicians' attitudes about multiplex tumor genomic testing. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Aleksandar Sekulic,et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. , 2012, The New England journal of medicine.
[12] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[13] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[14] I. Bièche,et al. Circulating tumor DNA as a non‐invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types , 2015, Molecular oncology.
[15] V. Servois,et al. Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents , 2012, British Journal of Cancer.
[16] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[17] Chris Sander,et al. Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.
[18] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[19] David Olmos,et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] P. Gestraud,et al. Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial , 2014, British Journal of Cancer.
[21] Michael Bittner,et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A. Eggermont,et al. Molecular screening for cancer treatment optimization (MOSCATO 01): A prospective molecular triage trial—Interim results. , 2013 .
[23] L. Garraway,et al. Attitudes of patients with cancer about personalized medicine and somatic genetic testing. , 2012, Journal of oncology practice.
[24] Daniel V.T. Catenacci,et al. Next‐generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity , 2014, Molecular oncology.
[25] Razelle Kurzrock,et al. Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative , 2012, Clinical Cancer Research.
[26] Thomas Bachelot,et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). , 2014, The Lancet. Oncology.
[27] Razelle Kurzrock,et al. Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses , 2014, Clinical Cancer Research.
[28] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.